According to Florida Hospital, approximately 80,000 women receive a gynecological cancer diagnosis in the United States each year. About half of all gynecological cancer diagnoses are uterine cancer, which contributes to 8,000 deaths each year while ovarian cancer causes 16,000 deaths annually. Oncolix saw a need for an improvement in the current treatment protocol, thus arose Prolanta (G129R).
Background Regarding Oncolix
Oncolix (Pink Sheets: AEPP) is a Houston-based biotechnology company dedicated to the improvement of cancer treatment. Oncolix’s management team has experience in various aspects of innovative pharmaceutical solutions including clinical development, trial management, manufacturing and licensure. Oncolix’s CEO, Michael Redman, has more than 25 years of experience in biotechnology and pharmaceuticals. He has consummated licensing deals with several revered pharmaceutical companies. The company’s main focus is centered around the drug Prolanta™, which has shown promising results as a breakthrough drug for gynecological cancer treatment. The company commenced operations …